151 related articles for article (PubMed ID: 19407314)
1. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L
Haematologica; 2009 May; 94(5):602-6. PubMed ID: 19407314
[TBL] [Abstract][Full Text] [Related]
2. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Zipperer E; Pelz D; Nachtkamp K; Kuendgen A; Strupp C; Gattermann N; Haas R; Germing U
Haematologica; 2009 May; 94(5):729-32. PubMed ID: 19336740
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
5. Management of older adults with myelodysplastic syndromes (MDS).
Luskin MR; Abel GA
J Geriatr Oncol; 2018 Jul; 9(4):302-307. PubMed ID: 29290596
[TBL] [Abstract][Full Text] [Related]
6. Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes.
Duarte FB; Santos TE; Barbosa MC; Kaufman J; Vasconcelos JP; Lemes RP; Rocha FD; Coutinho DF; Zalcberg I; Vasconcelos PR
Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():25-28. PubMed ID: 27982317
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
Cutler C
Hematology Am Soc Hematol Educ Program; 2010; 2010():325-9. PubMed ID: 21239814
[TBL] [Abstract][Full Text] [Related]
8. The role of hematopoietic stem cell transplantation in myelodysplastic syndrome.
Thompson JE; Luger SM
Oncology (Williston Park); 2005 Apr; 19(4):533-42; discussion 542-4, 547-8. PubMed ID: 15934520
[TBL] [Abstract][Full Text] [Related]
9. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.
Bammer C; Sperr WR; Kemmler G; Wimazal F; Nösslinger T; Schönmetzler A; Krieger O; Pfeilstöcker M; Valent P; Stauder R
J Geriatr Oncol; 2014 Jul; 5(3):299-306. PubMed ID: 24636334
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
11. Patient selection for transplantation in the myelodysplastic syndromes.
Cutler C
Hematol Oncol Clin North Am; 2010 Apr; 24(2):469-76. PubMed ID: 20359638
[TBL] [Abstract][Full Text] [Related]
12. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.
Abel GA; Buckstein R
Am Soc Clin Oncol Educ Book; 2016; 35():e337-44. PubMed ID: 27249740
[TBL] [Abstract][Full Text] [Related]
13. The message is not the median!
Deeg HJ
Mayo Clin Proc; 2004 Feb; 79(2):275; author reply 275-6. PubMed ID: 14959926
[No Abstract] [Full Text] [Related]
14. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.
Gattermann N; Kündgen A; Kellermann L; Zeffel M; Paessens B; Germing U
Eur J Haematol; 2013 Dec; 91(6):473-82. PubMed ID: 24102637
[TBL] [Abstract][Full Text] [Related]
15. [Hematopoietic stem cell transplantation for myelodysplastic syndromes].
Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):511-2. PubMed ID: 22967405
[No Abstract] [Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation for MDS.
Bartenstein M; Deeg HJ
Hematol Oncol Clin North Am; 2010 Apr; 24(2):407-22. PubMed ID: 20359634
[TBL] [Abstract][Full Text] [Related]
18. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.
Della Porta MG; Ambaglio I; Ubezio M; Travaglino E; Pascutto C; Malcovati L
Haematologica; 2012 Apr; 97(4):631-2. PubMed ID: 22271887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
